Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) announced that it has completed several critical milestones in February 2026 that bring its GraftAssureDx™ transplant rejection test closer to FDA approval. The company finished a three‑site reproducibility study on February 23 2026 at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health, and it achieved ISO 13485 certification on February 26 2026, confirming that its manufacturing and quality management systems meet international standards for medical devices.
The reproducibility study involved a statistically robust sample set that demonstrated consistent performance across the three sites, providing the data needed to support the De Novo submission. The study’s completion on February 23 2026 marks a significant step in validating the test’s analytical accuracy and clinical utility, key requirements for regulatory review.
ISO 13485 certification not only strengthens the company’s regulatory dossier but also opens the door to future submissions in the United Kingdom and the European Union. By meeting the quality management system requirements of the EU’s Medical Device Regulation, Insight positions itself to expand its market beyond the United States and tap into the growing demand for decentralized transplant diagnostics in those regions.
The company has also gathered a sufficient number of clinical samples—enough to satisfy the FDA’s evidence requirements for a De Novo submission. This sample pool supports the statistical power needed to demonstrate the test’s safety and effectiveness, a critical component of the regulatory filing.
GraftAssureDx is a digital‑PCR‑based kit that quantifies donor‑derived cell‑free DNA, a biomarker for transplant rejection. The product targets a market estimated at $1 billion to $2 billion, and the company’s partnership with Bio‑Rad Laboratories provides the digital PCR technology that underpins the assay’s performance. The combination of advanced analytics and a decentralized testing model positions GraftAssureDx to disrupt the traditional centralized laboratory model for transplant rejection testing.
Financially, Insight reported Q3 2025 revenue of $260,000 and a net loss of $10.9 million. For the full year 2024, revenue was $1.88 million with a loss of $60.93 million. In February 2026, the company raised $26 million through a registered direct offering, bolstering its cash position as it prepares for commercialization and regulatory milestones.
CEO Josh Riggs said the company is aiming to make 2026 the year transplant centers regain control of patient samples, emphasizing the strategic importance of the GraftAssureDx kit. Riggs also noted that the company is still preparing for a mid‑2026 launch and remains confident that the FDA authorization will transform transplant patient monitoring.
These milestones bring Insight closer to FDA submission and lay the groundwork for a potential market launch in 2026. The company’s progress on study completion, quality certification, and sample collection, combined with its financial backing and strategic partnerships, positions it to capitalize on a sizable transplant diagnostics market and to potentially shift the industry toward decentralized, in‑house testing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.